Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) a license to use its Enhanze technology to develop subcutaneous formulations of therapies against up to four targets, including a new formulation of ALXN1210. Halozyme will...

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of...

In a paper published in Nature Communications, researchers from the Novartis Institutes for BioMedical Research at Novartis AG (NYSE:NVS; SIX:NOVN) said they had developed a method to extend the half-life of therapies by three- to...